{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:20:10Z","timestamp":1787836810492,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008333","name":"University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011531","name":"University of Alabama","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jacl.2020.01.004","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T02:36:30Z","timestamp":1579746990000},"page":"260-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction"],"prefix":"10.1016","volume":"14","author":[{"given":"Todd M.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisandro D.","family":"Colantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Farkouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Limdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri L.","family":"Monda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Corina","family":"Serban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ransi M.","family":"Somaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Muntner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2020.01.004_bib1","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jacl.2020.01.004_bib2","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2020.01.004_bib3","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.jacl.2020.01.004_bib4","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","volume":"60","author":"Fihn","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2020.01.004_bib5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/01.CIR.0000112577.69066.CB","article-title":"Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes","volume":"109","author":"Mukherjee","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2020.01.004_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jama.293.3.349","article-title":"A simplified approach to the management of non-ST-segment elevation acute coronary syndromes","volume":"293","author":"Gluckman","year":"2005","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.jacl.2020.01.004_bib7","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Steg","year":"2012","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2020.01.004_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2020.01.004_bib9","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"73","author":"Gundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2020.01.004_bib10","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacl.2020.01.004_bib11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacl.2020.01.004_bib12","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.jacl.2020.01.004_bib13","first-page":"S103","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2020.01.004_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2020.01.004_bib33","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","article-title":"National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk","volume":"13","author":"Orringer","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2020.01.004_bib15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacl.2019.05.005","article-title":"Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit","volume":"13","author":"Robinson","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"22","key":"10.1016\/j.jacl.2020.01.004_bib16","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2020.01.004_bib17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/0002-8703(93)90182-9","article-title":"Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: The Framingham Study","volume":"125","author":"Cupples","year":"1993","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.jacl.2020.01.004_bib18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ahj.2015.04.027","article-title":"Trends in mortality and recurrent coronary heart disease events after an acute myocardial infarction among Medicare beneficiaries, 2001-2009","volume":"170","author":"Brown","year":"2015","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jacl.2020.01.004_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCOUTCOMES.110.957944","article-title":"Population trends of recurrent coronary heart disease event rates remain high","volume":"4","author":"Briffa","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacl.2020.01.004_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ahj.2016.01.021","article-title":"Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction","volume":"175","author":"Pilgrim","year":"2016","journal-title":"Am Heart J"},{"issue":"23","key":"10.1016\/j.jacl.2020.01.004_bib21","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1136\/heartjnl-2012-302532","article-title":"Trends and predictors of rehospitalisation following an acute coronary syndrome: report from the Australian and New Zealand population of the Global Registry of Acute Coronary Events (GRACE)","volume":"98","author":"Sangu","year":"2012","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.jacl.2020.01.004_bib22","doi-asserted-by":"crossref","first-page":"e001709","DOI":"10.1161\/JAHA.114.001709","article-title":"Trends in myocardial infarction secondary prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999-2012","volume":"4","author":"Shah","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.jacl.2020.01.004_bib23","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.amjcard.2014.03.006","article-title":"Trends in acute myocardial infarction event rates and risk of recurrences after an incident event in Norway 1994 to 2009 (from a cardiovascular disease in Norway project)","volume":"113","author":"Sulo","year":"2014","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.jacl.2020.01.004_bib24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1592\/phco.29.8.906","article-title":"Factors associated with recurrent coronary events among patients with cardiovascular disease","volume":"29","author":"McConnell","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.jacl.2020.01.004_bib25","first-page":"470","article-title":"Clinical outcomes and medication adherence in acute coronary syndrome patients with and without type 2 diabetes mellitus: a longitudinal analysis 2006-2011","volume":"21","author":"Cziraky","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jacl.2020.01.004_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCOUTCOMES.115.002365","article-title":"Predicting adverse outcomes after myocardial infarction among patients with diabetes mellitus","volume":"9","author":"Arnold","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"8 Suppl 3","key":"10.1016\/j.jacl.2020.01.004_bib27","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/MLR.0b013e31829b1d2a","article-title":"Standardizing terminology and definitions of medication adherence and persistence in research employing electronic data bases","volume":"51","author":"Raebel","year":"2013","journal-title":"Med Care"},{"issue":"2","key":"10.1016\/j.jacl.2020.01.004_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2020.01.004_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1477-7525-7-82","article-title":"Prevalence of multiple chronic conditions in the United States' Medicare population","volume":"7","author":"Schneider","year":"2009","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"10.1016\/j.jacl.2020.01.004_bib30","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/aje\/kwv116","article-title":"Optimal use of available claims to identify a Medicare population free of coronary heart disease","volume":"182","author":"Kent","year":"2015","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacl.2020.01.004_bib31","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1161\/CIRCULATIONAHA.118.035289","article-title":"A conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine","volume":"137","author":"Patel","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jacl.2020.01.004_bib32","doi-asserted-by":"crossref","first-page":"e001208","DOI":"10.1161\/JAHA.114.001208","article-title":"Statin use following hospitalization among Medicare beneficiaries with a secondary discharge diagnosis of acute myocardial infarction","volume":"4","author":"Yun","year":"2015","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420300040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287420300040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:34:34Z","timestamp":1761831274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287420300040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1933287420300040"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2020.01.004","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2020.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}